Loading clinical trials...
Loading clinical trials...
A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
Conditions
Interventions
E/C/F/TAF
Locations
70
United States
Maricopa Integrated Health System - McDowell Clinic
Phoenix, Arizona, United States
Pueblo Family Physicians
Phoenix, Arizona, United States
Health for Life Clinic PLLC
Little Rock, Arkansas, United States
Pacific Oaks Medical Group
Beverly Hills, California, United States
Kaiser Permanente
Hayward, California, United States
Long Beach Education and Research Consultants
Long Beach, California, United States
Start Date
March 27, 2013
Primary Completion Date
July 31, 2014
Completion Date
July 18, 2018
Last Updated
March 2, 2020
NCT01875588
NCT06598397
NCT06857071
NCT06627764
NCT07509853
NCT07512869
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions